Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+
Original source ↗  |  February 13, 2026 at 14:57 UTC  |  Finnhub - MRK

No analysis available.

Trade Ideas
Ticker Direction Speaker Thesis Time
MRK
NONE Finnhub News — —